Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 11월 2023 - 5:52AM
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company discovering and developing clinically
differentiated small molecule therapeutics targeting fundamental
biological pathways of cancer, today announced that on November 1,
2023, the Compensation Committee of Zentalis’ Board of Directors
granted non-qualified stock options to purchase an aggregate of
271,000 shares of the Company’s common stock to five newly hired
employees. The stock options were granted under the Zentalis
Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award
Plan (2022 Inducement Plan) as an inducement material to each
individual’s entering into employment with Zentalis in accordance
with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
Zentalis, or following a bona fide period of non-employment, as an
inducement material to such individuals’ entering into employment
with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $16.35 per share,
which is equal to the closing price of Zentalis’ common stock on
The Nasdaq Global Market on the date of grant. The stock options
have a 10-year term and will vest over four years, with 25% of the
options vesting on the first anniversary of the vesting
commencement date and the remaining 75% of the options vesting in
equal monthly installments over the three years thereafter. Vesting
of the stock options is subject to each employee’s continued
service to Zentalis on each vesting date.
About Zentalis PharmaceuticalsZentalis®
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
discovering and developing small molecule therapeutics targeting
fundamental biological pathways of cancers. Utilizing its
Integrated Discovery Engine, the Company is developing a focused
pipeline of potentially best-in-class oncology candidates, which
include azenosertib (ZN-c3), a WEE1 inhibitor for advanced solid
tumors, and ZN-d5, a BCL-2 inhibitor for hematologic malignancies
and related disorders. The Company is also leveraging its extensive
experience and capabilities across cancer biology and medicinal
chemistry to advance its research on protein degraders. Zentalis
has operations in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn at
www.linkedin.com/company/zentalis-pharmaceuticals.
Contact:
Katie Beach Oltsik Evoke
CanaleKatherine.Beach@evokegroup.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024